磷酸钙固化聚(L-谷氨酸)-顺铂/三氧化二砷纳米团簇协同治疗腹腔转移卵巢癌

姜中雨; 冯祥汝; 许维国; 庄秀丽; 丁建勋; 陈学思

doi:10.11777/j.issn1000-3304.2020.20053

您当前的位置：

首页 >

文章列表页 >

磷酸钙固化聚(L-谷氨酸)-顺铂/三氧化二砷纳米团簇协同治疗腹腔转移卵巢癌

论文 | 更新时间：2021-01-26

- 磷酸钙固化聚(L-谷氨酸)-顺铂/三氧化二砷纳米团簇协同治疗腹腔转移卵巢癌
- Calcium Phosphate-cured Nanocluster of Poly(L-glutamic acid)-Cisplatin and Arsenic Trioxide for Synergistic Chemotherapy of Peritoneal Metastasis of Ovarian Cancer
- 高分子学报 2020年51卷第8期页码：901-910
- 作者机构：
  
  1.中国科学院长春应用化学研究所中国科学院生态环境高分子材料重点实验室　长春 130022
  2.中国科学技术大学应用化学与工程学院　合肥 230026
- 作者简介：
  
  E-mail: jxding@ciac.ac.cn Jian-xun Ding, E-mail:jxding@ciac.ac.cn
- 基金信息：
  
  国家自然科学基金(基金号51973216，51873207，51833010)资助项目
- DOI：10.11777/j.issn1000-3304.2020.20053
  中图分类号：
- 纸质出版日期：2020-8，
  
  网络出版日期：2020-7-22，
  
  收稿日期：2020-3-4，
  
  修回日期：2020-4-30，
扫描看全文
姜中雨, 冯祥汝, 许维国, 庄秀丽, 丁建勋, 陈学思. 磷酸钙固化聚(L-谷氨酸)-顺铂/三氧化二砷纳米团簇协同治疗腹腔转移卵巢癌[J]. 高分子学报, 2020,51(8):901-910.

Zhong-yu Jiang, Xiang-ru Feng, Wei-guo Xu, Xiu-li Zhuang, Jian-xun Ding, Xue-si Chen. Calcium Phosphate-cured Nanocluster of Poly(L-glutamic acid)-Cisplatin and Arsenic Trioxide for Synergistic Chemotherapy of Peritoneal Metastasis of Ovarian Cancer[J]. Acta Polymerica Sinica, 2020,51(8):901-910.
姜中雨, 冯祥汝, 许维国, 庄秀丽, 丁建勋, 陈学思. 磷酸钙固化聚(L-谷氨酸)-顺铂/三氧化二砷纳米团簇协同治疗腹腔转移卵巢癌[J]. 高分子学报, 2020,51(8):901-910. DOI： 10.11777/j.issn1000-3304.2020.20053.

Zhong-yu Jiang, Xiang-ru Feng, Wei-guo Xu, Xiu-li Zhuang, Jian-xun Ding, Xue-si Chen. Calcium Phosphate-cured Nanocluster of Poly(L-glutamic acid)-Cisplatin and Arsenic Trioxide for Synergistic Chemotherapy of Peritoneal Metastasis of Ovarian Cancer[J]. Acta Polymerica Sinica, 2020,51(8):901-910. DOI： 10.11777/j.issn1000-3304.2020.20053.

摘要

在临床上，顺铂(CDDP)作为一线化疗药物被广泛应用于治疗各种实体肿瘤. 然而，肿瘤细胞内的还原微环境会降低CDDP的疗效. 在本研究中，通过磷酸钙固化技术将聚(L-谷氨酸)-CDDP纳米粒子(PGN-Pt)与三氧化二砷(ATO)结合，构建细胞内酸敏感的纳米团簇NC

PGN-Pt+ATO

，以提高肿瘤治疗效果. NC

PGN-Pt+ATO

为粒径在129.8 nm的纳米球，能够在血液中长循环并通过增强渗透与滞留效应在肿瘤组织富集. NC

PGN-Pt+ATO

被细胞摄取后在细胞内酸性环境中释放PGN-Pt和ATO. PGN-Pt在细胞内持续释放CDDP以保持其有效杀伤浓度. CDDP和ATO共同提高细胞内活性氧的水平杀死肿瘤细胞，同时提升CDDP的疗效协同抑制肿瘤进展. 鉴于良好的有效性和安全性，NC

PGN-Pt+ATO

为CDDP纳米药物的设计提供了新的有效策略.

Abstract

Cisplatin (CDDP)

as a traditional first-line chemotherapeutic drug

has been broadly used for the treatment of numerous solid cancers in the clinic. However

the treatment efficacy of CDDP is limited by a variety of issues

including enhanced efflux

increased detoxification capability

and improved ability of DNA damage repair of cancer cells. For example

the high level of intracellular glutathione (GSH) significantly decreases the cytotoxicity of CDDP through the formation of stable GS-Pt complex

which can be rapidly extracted from the tumor cells through an adenosine triphosphate-dependent glutathione S-conjugate export pump (GS-X pump). Therefore

the antitumor efficacy of CDDP can be upregulated by inhibiting the synthesis of GSH with drugs

directly depleting GSH with organic or inorganic nanoparticles

or neutralizing GSH through upregulating the level of reactive oxygens species (ROS) in the cells. Herein

the intracellular acidity-sensitive nanocluster (NC

PGN-Pt+As

) was developed to improve the antitumor efficacy

which was fabricated by the calcium phosphate (Ca

(PO

)

)-curing of CDDP-loaded poly(L-glutamic acid) nanoparticle (PGN-Pt) and arsenic trioxide (ATO). The optimal mass ratio of CDDP and ATO in NC

PGN-Pt+As

was determined to be 2:1 by the coefficient of drug interaction (CDI) between CDDP and ATO. NC

PGN-Pt+As

exhibited a nanosphere structure with a diameter of 129.8 nm. NC

PGN-Pt+As

showed prolonged blood circulation

evidenced by the increased half-life (

1/2

) and the area under the drug concentration-time curve (AUC

). Moreover

PGN-Pt+As

demonstrated the reduced accumulation in the normal tissues and improved accumulation in the tumor. The intratumoral accumulations of CDDP and ATO were 5.7 and 3.9 times higher than those of the free CDDP+ATO group

respectively

which should be attributed to the enhanced permeability and retention effect. Upon entering the endosome

PGN-Pt+As

decomposed and released PGN-Pt and ATO under the acidic conditions. CDDP was sustainedly released from PGN-Pt in the cells and maintained effective concentration. CDDP and ATO synergistically upregulated the level of intracellular ROS

which could kill tumor cells or enhance the efficacy of CDDP and synergistically inhibit peritoneal metastasis of ovarian cancer. At the same time

PGN-Pt+As

was proved safe by the remained body weights of mice during the treatment period and normal levels of the liver- and kidney-related parameters after all treatments relative to free CDDP+ATO. Given its excellent efficacy and safety

this platform provided a uniquely effective strategy for the design of CDDP nanomedicines.

关键词

高分子纳米药物三氧化二砷磷酸钙纳米团簇细胞内药物递送癌症协同化疗

Keywords

Polymer nanomedicineArsenic trioxideCalcium phosphate nanoclusterIntracellular drug deliverySynergistic chemotherapy of cancer

references

Rosenberg B, Van Camp L, Krigas T. Nature , 1965 . 205 ( 4972 ): 698 - 699 . DOI:10.1038/205698a0http://doi.org/10.1038/205698a0 .

Xiao H H, Yan L S, Dempsey E M, Song W T, Qi R G, Li W L, Huang Y B, Jing X B, Zhou D F, Ding J X, Chen X S. Prog Polym Sci , 2018 . 87 70 - 106 . DOI:10.1016/j.progpolymsci.2018.07.004http://doi.org/10.1016/j.progpolymsci.2018.07.004 .

Amable L. Pharmacol Res , 2016 . 106 27 - 36 . DOI:10.1016/j.phrs.2016.01.001http://doi.org/10.1016/j.phrs.2016.01.001 .

Jaykumar A B, Karra A S, Cobb M H. Cancer Cell , 2018 . 34 ( 2 ): 183 - 185 . DOI:10.1016/j.ccell.2018.07.010http://doi.org/10.1016/j.ccell.2018.07.010 .

Kasiappan R, Safe S H. React Oxygen Species , 2016 . 1 ( 1 ): 22 - 37 . DOI:10.20455/ros.2016.805http://doi.org/10.20455/ros.2016.805 .

Shen W, Liu W, Yang H, Zhang P, Xiao C, Chen X. Biomaterials , 2018 . 178 706 - 719 . DOI:10.1016/j.biomaterials.2018.02.011http://doi.org/10.1016/j.biomaterials.2018.02.011 .

Akhtar M J, Ahamed M, Alhadlaq H A, Alrokayan S A. J Trace Elem Med Bio , 2018 . 50 283 - 290 . DOI:10.1016/j.jtemb.2018.07.016http://doi.org/10.1016/j.jtemb.2018.07.016 .

Li X, Wang H, Wang J, Chen Y, Yin X, Shi G, Li H, Hu Z, Liang X. BMC Cancer , 2016 . 16 ( 1 ): 578 DOI:10.1186/s12885-016-2640-3http://doi.org/10.1186/s12885-016-2640-3 .

Chen X C, Hong Y, Zheng P P, You X H, Feng J H, Huang Z H, Wang Y. Cancer , 2019 . 126 ( 2 ): 311 - 321.

Peng Y B, Zhao Z L, Liu T, Li X, Hu X X, Wei X P, Zhang X B, Tan W H. Angew Chem Int Ed , 2017 . 56 ( 36 ): 10845 - 10849 . DOI:10.1002/anie.201701366http://doi.org/10.1002/anie.201701366 .

Nakaoka T, Ota A, Ono T, Karnan S, Konishi H, Furuhashi A, Ohmura Y, Yamada Y, Hosokawa Y, Kazaoka Y. Cell Oncol , 2014 . 37 ( 2 ): 119 - 129 . DOI:10.1007/s13402-014-0167-7http://doi.org/10.1007/s13402-014-0167-7 .

Chen J, Ding J, Wang Y, Cheng J, Ji S, Zhuang X, Chen X. Adv Mater , 2017 . 29 ( 32 ): 1701170 DOI:10.1002/adma.201701170http://doi.org/10.1002/adma.201701170 .

Zhang Zhen(张震), He Chaoliang(贺超良), Xu Qinghua(徐清华), Zhuang Xiuli(庄秀丽), Chen Xuesi(陈学思). Acta Polymeric Sinica(高分子学报) , 2018 . ( 1 ): 99 - 108 . DOI:10.11777/j.issn1000-3304.2018.17221http://doi.org/10.11777/j.issn1000-3304.2018.17221 .

Jiang Zhongyu(姜中雨), Liu Yixuan(刘仪轩), Feng Xiangru(冯祥汝), Ding Jianxun(丁建勋). J Funct Polym(功能高分子学报) , 2019 . 32 ( 1 ): 13 - 27.

Jiang Z, Chen J, Cui L, Zhuang X, Ding J, Chen X. Small Methods , 2018 . 2 ( 3 ): 1700307 DOI:10.1002/smtd.201700307http://doi.org/10.1002/smtd.201700307 .

Yu H Y, Tang Z H, Li M Q, Song W T, Zhang D W, Zhang Y, Yang Y, Sun H, Deng M X, Chen X S. J Biomed Nanotechnol , 2016 . 12 ( 1 ): 69 - 78 . DOI:10.1166/jbn.2016.2152http://doi.org/10.1166/jbn.2016.2152 .

Kong R, Sun B, Jiang H C, Pan S H, Chen H, Wang S J, Krissansen G W, Sun X Y. Cancer Lett , 2010 . 291 ( 1 ): 90 - 98 . DOI:10.1016/j.canlet.2009.10.001http://doi.org/10.1016/j.canlet.2009.10.001 .

Nomoto T, Fukushima S, Kumagai M, Miyazaki K, Inoue A, Mi P, Maeda Y, Toh K, Matsumoto Y, Morimoto Y, Kishimura A, Nishiyama N, Kataoka K. Biomater Sci , 2016 . 4 ( 5 ): 826 - 838 . DOI:10.1039/C6BM00011Hhttp://doi.org/10.1039/C6BM00011H .

Pittella F, Zhang M Z, Lee Y, Kim H J, Tockary T, Osada K, Ishii T, Miyata K, Nishiyama N, Kataoka K. Biomaterials , 2011 . 32 ( 11 ): 3106 - 3114 . DOI:10.1016/j.biomaterials.2010.12.057http://doi.org/10.1016/j.biomaterials.2010.12.057 .

Zheng P, Liu Y, Chen J, Xu W, Li G, Ding J. Chin Chem Lett , 2020 . 31 ( 5 ): 1178 - 1182 . DOI:10.1016/j.cclet.2019.12.001http://doi.org/10.1016/j.cclet.2019.12.001 .

Zhang S L, Li J, Lykotrafitis G, Bao G, Suresh S. Adv Mater , 2009 . 21 ( 4 ): 419 - 424 . DOI:10.1002/adma.200801393http://doi.org/10.1002/adma.200801393 .

Xu W G, Ding J X, Xiao C S, Li L Y, Zhuang X L, Chen X S. Biomaterials , 2015 . 54 72 - 86 . DOI:10.1016/j.biomaterials.2015.03.021http://doi.org/10.1016/j.biomaterials.2015.03.021 .

Yu Y, Xu Q, He S, Xiong H, Zhang Q, Xu W, Ricotta V, Bai L, Zhang Q, Yu Z. Coord Chem Rev , 2019 . 387 154 - 179 . DOI:10.1016/j.ccr.2019.01.020http://doi.org/10.1016/j.ccr.2019.01.020 .

Chen C, Li Y, Yu X, Jiang Q, Xu X, Yang Q, Qian Z. Chin Chem Lett , 2018 . 29 ( 11 ): 1609 - 1612 . DOI:10.1016/j.cclet.2018.02.010http://doi.org/10.1016/j.cclet.2018.02.010 .

Wang J, Xu W, Li S, Qiu H, Li Z, Wang C, Wang X, Ding J. J Biomed Nanotechnol , 2018 . 14 ( 12 ): 2102 - 2113 . DOI:10.1166/jbn.2018.2624http://doi.org/10.1166/jbn.2018.2624 .

Wang G, Wang Z, Li C, Duan G, Wang K, Li Q, Tao T. Biomed Pharmacother , 2018 . 106 275 - 284 . DOI:10.1016/j.biopha.2018.06.137http://doi.org/10.1016/j.biopha.2018.06.137 .

Lu Y P, Han S P, Zheng H Y, Ma R, Ping Y T, Zou J F, Tang H X, Zhang Y P, Xu X L, Li F Z. Int J Nanomed , 2018 . 13 5937 - 5952 . DOI:10.2147/IJN.S175418http://doi.org/10.2147/IJN.S175418 .

Zhang Y, Cai L, Li D, Lao Y H, Liu D, Li M, Ding J, Chen X. Nano Res , 2018 . 11 ( 9 ): 4806 - 4822 . DOI:10.1007/s12274-018-2066-0http://doi.org/10.1007/s12274-018-2066-0 .

更多指标>

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据